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Pharmaceuticals and Biopiracy: How the 
America Invents Act May Reduce the 
Misappropriation of Traditional Medicine 
Ryan Levy* and Spencer Green** 
For decades, Eastern traditional medicine has been 
misappropriated by others who claim it as their own and attempt 
to obtain patent protection for it. As long this practice has 
existed, the international community has pushed back against it. 
Several countries and international bodies have created 
databases of traditional knowledge, hoping to preclude the 
issuance of patents on that knowledge. Other countries, like 
Thailand, have extended intellectual property protection to the 
traditional knowledge stakeholders themselves. However, a 
recent change to U.S. patent law may have the unintended 
consequence of helping resolve the issue of biopiracy. 
Prior to the passage of the America Invents Act, a foreign 
invention could only serve as prior art to U.S. patents if the 
foreign invention itself was patented or if it was described in a 
printed publication. Because much traditional knowledge was 
never recorded, U.S. law did not consider it to be prior art. This 
allowed corporations to obtain patent protection for traditional 
medicine, even though indigenous peoples had been using it for 
centuries.  
The America Invents Act, however, eliminated the requirement 
that a public use occur “in this country” to constitute prior art. 
As a result, public use of traditional knowledge anywhere in the 
world renders it prior art to all subsequent U.S. patent 
applications. This article analyzes how this dramatic shift in the 
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scope of available prior art affects the patent strategies of 
companies and provides different remedies to traditional 
knowledge stakeholders. 
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I. INTRODUCTION 
In 1995, two Indian immigrants at the University of Mississippi 
Medical Center obtained a U.S. patent entitled “Use of turmeric in 
wound healing” (the “Tumeric Patent”).1 The patent acknowledged that 
turmeric had been used “in India as a traditional medicine for the 
treatment of various sprains and inflammatory conditions.”2 However, 
this patent purported to put turmeric to a new use based on “experimental 
                                                                                                             
1 U.S. Patent No. 5,401,504 col. 1 l. 37-39 (filed Dec. 28, 1993); see also Prithwiraj 
Choudhury & Tarun Khanna, Bio-Piracy or Prospering Together? Fuzzy Set and 
Qualitative Analysis of Herbal Patenting by Firms 24 (Harvard Bus. Sch., Working Paper 
14-081, 2014) [hereinafter Choudhury & Khanna, Bio-Piracy], available at http://www.
hbs.edu/faculty/Publication%20Files/14-081_6cfa4f81-d5cb-44f6-9a0c-1fe7c91f61ef.
pdf. 
2 ‘504 Patent., supra note 1 col. 1 l. 37-39 (filed Dec. 28, 1993). 
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evidence.”3 The inventors claimed a “method of promoting healing of a 
wound in a patient, which consists essentially of administering a wound-
healing agent consisting of an effective amount of turmeric powder to 
said patient.”4 The problem is that turmeric had, in fact, been used in 
wound healing for millennia.5 
Because of the widespread use of turmeric for wound healing, 
particularly in India, this patent had the potential to have significant 
effects. Indians living in America could infringe the patent by using this 
home remedy and Indian companies would be subject to liability if they 
exported goods to the United States that used the remedy.6 In response, 
the Indian Council of Scientific and Industrial Research (CSIR) sought 
reexamination of the patent.7 It demonstrated, through ancient Sanskrit 
texts and academic publications, that the patented method lacked 
novelty.8 The United States Patent and Trademark Office (USPTO) 
issued a Reexamination Certificate in 1998 cancelling every claim of the 
patent.9 Thus, with respect to the Turmeric Patent, the patent system 
corrected itself. A bad patent was issued on traditional medicine, adverse 
parties utilized the available administrative procedures, and the USPTO 
cancelled the claims. 
However, due to geographic limitations on prior art, patents based on 
or claiming traditional knowledge are not always invalidated. Many 
traditional knowledge stakeholders do not have the benefit of printed 
publications embodying their knowledge. Under pre-America Invents 
Act (AIA) law, patents on that knowledge remain valid.10 Moreover, the 
mere grant of a patent on a method for using turmeric in wound healing 
brought about significant social harm, despite its later invalidation. A 
remedy that the Indian people had utilized for thousands of years was 
now owned by the University of Mississippi Medical Center.11 The 
Indian people were outraged that a patent had been granted on 
                                                                                                             
3 Id. 
4 Id. col. 3 l. 4-7. 
5 Choudhury & Khanna, Bio-Piracy, supra note 1, at 23. 
6 See 35 U.S.C. § 271(a) (2012) (providing that “whoever without authority makes, 
uses, offers to sell, or sells any patented invention, within the United States or imports 
into the United States any patented invention during the term of the patent therefor, 
infringes the patent.”). 
7 TOBIAS KIENE, THE LEGAL PROTECTION OF TRADITIONAL KNOWLEDGE IN THE 
PHARMACEUTICAL FIELD 17 (2011). 
8 Id; ‘504 Patent., supra note 1 Reexamination Certificate (issued Apr. 21, 1998). 
9 Id. 
10 Patents issued before March 18, 2013 are governed by the Patent Act, rather than by 
the America Invents Act. Medisim Ltd. v. BestMed, LLC, 758 F.3d 1352, 1354 n.1 (Fed. 
Cir. 2014). Under the Patent Act, foreign inventions were not regarded as prior art unless 
they were “patented or described in a printed publication.” 35 U.S.C. § 102(a) (2006). 
11 Choudhury & Khanna, Bio-Piracy, supra note 1, at 23. 
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“something that has been the collective wisdom of a people for 
centuries.”12 
The USPTO has received tens of thousands of patent applications 
relating to traditional uses of Indian and Chinese herbal remedies.13 
However, a recent change in U.S. patent law will affect whether such 
patents continue to be granted, whether they are enforced, and how the 
patent claims are drafted. Prior to the passage of the America Invents Act 
(AIA),14 foreign public use, sale, or knowledge of these traditional 
remedies was not regarded as “prior art” to U.S. patents.15 As a result, 
even if traditional remedies had been used for thousands of years outside 
the United States, they could not be used to invalidate a U.S. patent 
unless they were published.16 The AIA changed that by eliminating the 
“in this country” limitation to those types of prior art.17 
This article addresses how the America Invents Act will affect the 
patent strategies of pharmaceutical companies seeking U.S. patents based 
on traditional medicine. It also discusses whether the AIA has created a 
new avenue through which traditional knowledge stakeholders may 
invalidate patents based on traditional medicine. Part I provides 
background on the history of geographic limitations to prior art under 
U.S. patent law. Part II discusses biopiracy, how it affects traditional 
knowledge stakeholders, and how Western firms have responded to 
charges that they expropriated traditional knowledge. Part III discusses 
the various measures that governmental entities and international bodies 
have taken in order to combat biopiracy. Part IV identifies and discusses 
the particular changes to the U.S. patent system under the AIA that may 
affect pharmaceutical companies’ ability to obtain protection for 
inventions based on traditional knowledge. 
                                                                                                             
12 Id. at 26. 
13 Prithwiraj Choudhury & Tarun Khanna, Codifying Prior Art and Patenting: Natural 
Experiment of Herbal Patent Prior Art Adoption at the EPO and USPTO 15 (Harvard 
Bus. Sch., Working Paper No, 14-079, 2014) [hereinafter Choudhury & Khanna, Prior 
Art], available at http://www.hbs.edu/faculty/Publication%20Files/14-079_9f881e56-
002c-4603-a778-5a698184c827.pdf. 
14 Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011) 
(codified at 35 U.S.C. §§ 1–390 (2011)) [hereinafter America Invents Act or AIA]. 
15 35 U.S.C. § 102(a) (2006). 
16 Id. 
17 See 35 U.S.C. § 102(a) (2012). 
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II. A BRIEF HISTORY OF GEOGRAPHIC LIMITATIONS ON PRIOR 
ART  
Geographic limitations on prior art have been a long-standing feature 
of U.S. patent law following passage of the Patent Act of 1836.18 Before 
the advent of airplanes and the Internet, which carry products and 
information rapidly across the world, geographic limitations on prior art 
enabled American “inventors”—who sought to commercially exploit 
foreign inventions in this country—to receive patents on that technology, 
despite not having invented it.19 Nonetheless, these patents were 
arguably consistent with the Constitution’s Intellectual Property Clause, 
which grants Congress the power “to promote the progress of science 
and the useful arts.”20 These entrepreneurs introduced to the United 
States new technology that would otherwise be unavailable, thereby 
promoting the progress of science in this country.21 In the modern world, 
however, geographic limitations on prior art are no longer required to 
ensure that new technology is made available across seas. Advances in 
how people trade information globally also reduce the burden of 
examining patent applications in light of all prior art, wherever it may be 
found. 
The U.S. patent system seeks to do more than simply encourage the 
introduction of new products into American markets. There are costs 
associated with granting monopolies to patent holders and removing 
information from the public domain. To properly balance those costs 
against the social and economic benefits of the introduction of new 
technology, the Framers understood the Intellectual Property Clause to 
embody certain limitations. Patents may not be granted to non-inventors, 
and inventions in the public domain may not be removed from the public 
domain.22 Modern patent law reflects those understandings by granting 
patent protection only to inventors who have “invent[ed] or 
discover[ed]” technologies23 that are useful,24 novel,25 non-obvious,26 
                                                                                                             
18 Patent Act of 1836, ch. 357, 5 Stat. 117, Sec. 7 (1836). (providing that a patent shall 
only issue if the invention “had [not] been invented or discovered by any other person in 
this country prior to the alleged invention or discovery thereof by the applicant . . . or 
described in any printed publication in this or any foreign country.”). 
19 If, however, each of the claim limitations was embodied in a printed publication, a 
U.S. patent would be denied. See id. 
20 U.S. CONST. art I, § 8, cl. 8. 
21 See Margo A. Bagley, Patently Unconstitutional, 87 MINN. L. REV. 679, 684 (2003) 
(arguing that geographic limitations on prior art are unconstitutional because they permit 
the patenting of inventions in the public domain). 
22 Id. 
23 35 U.S.C. § 101 (2012). 
24 Id. 
25 35 U.S.C. § 102 (2012). 
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and enabled.27 By eliminating geographic restrictions on prior art, the 
America Invents Act has broadened the scope of prior art in a way that 
may prevent future patents on traditional knowledge. In doing so, it will 
help ensure that the U.S. patent system does not prejudice the public or 
harm traditional knowledge stakeholders. 
III. THE PROBLEM OF BIOPIRACY 
“Biopiracy” describes circumstances in which “developed countries 
use biotechnology patents to expropriate the biological [or] genetic 
heritage of less developed countries.”28 Accusations of biopiracy 
typically involve the theft of traditional knowledge that is otherwise held 
by indigenous people.29 The textbook example involves valuable uses of 
local plants or animals within a particular indigenous community. 
Corporations may become aware of these uses, then seek to patent and 
commercialize that knowledge for their own gain.30 Companies often 
attempt to patent rights in indigenous knowledge or the products and 
methods derived from that knowledge.31 As such, the patentee may 
receive significant financial compensation for their patent rights, while 
leaving the indigenous community with no gain. 
A. Biopiracy in the Pharmaceutical Industry 
Due to the medicinal nature of much traditional knowledge, 
pharmaceutical companies are among the most common perpetrators of 
biopiracy. Consumers often have allergies to drugs or simply desire to 
avoid the side effects associated with such medicines.32 As a result, the 
market for pharmaceutical products based on traditional knowledge is 
growing, and pharmaceutical companies seek to take advantage.33 These 
companies frequently become aware of traditional remedies for common 
medical problems, then commercialize and patent some variation of 
                                                                                                             
26 35 U.S.C. § 103 (2012). 
27 35 U.S.C. § 112 (2012). 
28 Baruch A. Brody, Traditional Knowledge and Intellectual Property, 20 KENNEDY 
INST. OF ETHICS J. 231 (2010). 
29 Id. 
30 Id. at 232. 
31 Peter Drahos, Indigenous Knowledge, Intellectual Property and Biopiracy, 22 EUR. 
INTELL. PROP. REV. 245 (2000). 
32 J. Maheswari, Patenting Indian Medicinal Plants and Products, 4 INDIAN J. SCIENCE 
& TECH. 298, 300 (2011). 
33 See Chika A. Ezeanya, Contending Issues of Intellectual Property Rights Protection 
and Indigenous Knowledge of Pharmacology in Africa South of the Sahara, 6 J. PAN AFR. 
STUD. 24, 29 (2013). 
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those remedies for their own benefit. The USPTO receives literally 
thousands of patent applications that relate in some way to traditional 
knowledge.34 
Below are a few of the most well-known instances of pharmaceutical 
biopiracy. These examples reflect the complexity of the issues, the 
varying cultural perceptions on the commercialization of traditional 
medicine, and the limits of the patent system’s ability to resolve these 
conflicts. 
i. Kwao krua 
The Thai herb kwao krua had been used for over 100 years and its 
medicinal uses had been documented in Thai writings as early as 1931.35 
More recently, however, certain plant-produced hormones have been 
discovered in the plant.36 These hormones have been used in modern 
medicine to enhance male sexual performance, enlarge and firm breasts, 
and firm the skin.37 A company based in South Korea holds a U.S. patent 
on an extract from kwao krua for some of these purposes.38 
The concern for the Thai people is that the steps for extraction 
disclosed in the patent do not differ from the methods that practitioners 
of traditional medicine have used for nearly a century.39 Unfortunately, 
publications discussing this practice were not considered as prior art to 
the U.S. patent.40 Threats of legal action have disrupted local producers 
of kwao krua and the plant has been harvested quickly for commercial 
purposes, which does not allow time for the plant’s regrowth.41 Due to 
the grant of intellectual property protection in this traditionally used plant 
and its extract, indigenous peoples’ customs relating to the plant’s 
ordinary production and use have been disturbed.42 
ii. Hoodia 
The San people of the Kalahari Desert in South Africa have been 
using Hoodia, a local plant, as an appetite-suppressant since ancient 
                                                                                                             
34 Choudhury & Khanna, Prior Art, supra note 1, at 15. 
35 DANIEL F. ROBINSON, CONFRONTING BIOPIRACY: CHALLENGES, CASES AND 
INTERNATIONAL DEBATES 55 (2010). 
36 Id. 
37 Id. 
38 U.S. Patent No. 6,673,377 (filed Aug. 28, 2000). 
39 ROBINSON, supra note 35, at 55. 
40 See id. 
41 Id. at 59. 
42 See id. 
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times.43 Suppressing their appetite by consuming Hoodia allowed them 
to engage in longer hunting expeditions and carry fewer supplies, 
increasing the productivity of the hunts.44 Pursuant to an international 
treaty, the Convention on Biodiversity (CBD), the San people have 
received royalty payments for the sales of drugs containing Hoodia by 
multinational pharmaceutical companies.45 However, serious questions 
remain about the fairness and propriety of such profit-sharing 
agreements.46 Moreover, the United States is not a party to the CBD, so 
profits gained through the exploitation of the U.S. patents on Hoodia 
result in no benefit to the San people.47 Thus, numerous patents that 
incorporate the San people’s indigenous knowledge of Hoodia have been 
granted in both the United States and Europe, with little or no benefit 
from the sales of products protected by those patents to the San people. 
iii. Madagascar rosy periwinkle 
The commercialization of the healing properties of the Madagascar 
rosy periwinkle is another example of a pharmaceutical company reaping 
the rewards of Eastern medicinal plants. The plant had been long used in 
traditional medicine by the indigenous communities of Madagascar, 
among others.48 Inspired by the use of this plant in traditional medicine, 
Eli Lilly & Company49 isolated two extracts that give the plant its 
healing properties: vinblastine and vincristine.50 Those extracts are now 
used in drugs the company markets for the treatment of cancer.51 Eli Lily 
receives around $100 million each year from these drugs, but the 
indigenous peoples of Madagascar do not share in the profits.52 
                                                                                                             
43 Fritz Dolder, Traditional Knowledge and Patenting: The Experience of the 
Neemfungicide and the Hoodia Cases, 26 BIOTECHNOLOGY L. REP. 583, 587 (2007). 
44 Id. 
45 Saskia Vermeylen, Contextualizing ‘Fair’ and ‘Equitable’: The San’s Reflections on 
the Hoodia Benefit-Sharing Agreement, 12 LOC. ENV’T 423, 428 (2007). 
46 See generally id. (discussing the San people’s perceptions of the fairness of the 
Hoodia Benefit Sharing Agreement); see infra Part I.C. 
47 List of Parties, CONVENTION ON BIOLOGICAL DIVERSITY, 
http://www.cbd.int/information/parties.shtml (last visited Mar. 29, 2015) (listing the 
parties to the CBD). 
48 Michael Hassemer, Genetic Resources, in INDIGENOUS HERITAGE AND 
INTELLECTUAL PROPERTY, 151, 168 (ed. Silke von Lewinski 2004). 
49 Eli Lilly & Company has approximately 39,000 employees worldwide, markets 
products in 125 countries, and had net sales of over $23 billion in 2013. Key Facts, ELI 
LILLY & CO., http://www.lilly.com/about/key-facts/Pages/key-facts.aspx (last visited 
Mar. 29, 2015). 
50 Hassemer, supra note 48 at 168. 
51 Id. 
52 Id. 
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Despite the perceived misappropriation of Malagasy culture, 
Malagasy healers never used the rosy periwinkle for the uses to which 
Eli Lilly is putting it. They used it primarily in treating diabetes.53 
Because Eli Lilly used the plant to produce new compounds, for new 
medicinal uses, they may be able to obtain patent protection even under 
the America Invents Act.54 However, the expanded scope of prior art 
under the new Section 102 will not be without impact on Eli Lilly’s 
ability to patent these sorts of inventions. Consideration of the Malagasy 
use may force companies like Eli Lilly to narrow their patent claims, 
directing them only at the new innovation. Accordingly, even where 
prior art may not entirely bar new patents, its consideration may affect 
the reach of new patent claims. 
B. Negative Consequences of Biopiracy 
The greatest criticism of the expropriation of indigenous medical 
knowledge by for-profit companies is that it is simply unfair.55 These 
critics argue that pharmaceutical companies are permitted to realize 
millions of dollars in sales from some traditional remedies with little or 
no payment to the actual indigenous knowledge holders.56 Critics of the 
Turmeric Patent leaned heavily on the perceived unfairness of patenting 
a remedy that had been used to heal wounds in India for hundreds of 
years.57 It was also an issue in Eli Lilly’s use of the Madagascar rosy 
periwinkle, which generates $100 million in sales for the company 
annually.58 Ironically, the patenting of traditional knowledge may cause 
the sale of products embodying traditional knowledge to the traditional 
knowledge holders at monopoly prices.59 Such sales, however, would 
                                                                                                             
53 Id. 
54 The AIA would consider medicinal uses of the plant that were known to the public 
to be prior art. 35 U.S.C. § 102 (2012). 
55 See e.g., Lester I. Yano, Protection of the Ethnobiological Knowledge of Indigenous 
Peoples, 41 UCLA L. REV. 443, 445 (arguing that permitting drug developers to profit off 
indigenous knowledge without compensating indigenous practitioners “is unfair and 
hypocritical.”); David Conforto, J. ENVTL. L. & LITIG. 357, 365 (acknowledging the 
perceived unfairness of geographic restrictions on prior art). But see generally Jim Chen, 
37 MCGEORGE L. REV. 1 (arguing that biopiracy is only a perceived problem, not an 
actual problem, and that the “biopiracy narrative” is false). 
56 See e.g., Yano, supra note 55. 
57 See Choudhury & Khanna, Bio-Piracy, supra note 1, at 25-26. 
58 Hassemer, supra note 48, at 168. 
59 Martin Khor, IPRs, Biodiversity, and the Theft of Indigenous Knowledge, 28 
INTERDISC. SCI. REVIEWS 7, 8 (2003). 
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have to occur within the United States to obtain the benefit of the 
monopoly a U.S. patent would provide.60 
The most egregious examples of the exploitation of traditional 
knowledge can occur when individuals and companies are prevented 
from utilizing knowledge that they had been using for centuries. An 
American patent does not preclude exportation of the patented invention 
to foreign countries, but it does prevent importation of products 
embodying the claimed invention to the U.S.61 Due to the threat of legal 
action, many such entities in countries that serve as the source of 
traditional knowledge have been precluded from using that knowledge.62 
For instance, despite a history of the use of kwao krua by the indigenous 
people of Thailand, threats of legal action have disrupted local 
production of the herb.63 
In India, individuals and companies had been using extract from 
neem trees for centuries to repel insects and bacterial diseases.64 Once a 
patent on a variation of this extract was granted to W.R. Grace & Co., the 
company sought to force Indian companies producing neem-based 
products to license its technology.65 Local companies feared that this 
patent would preclude them from exporting goods to the U.S. market and 
would drive up the price of neem seeds.66 By depriving Indian companies 
of their ability to export certain neem-based products to the world’s 
largest economy, the neem patent deprived Indian people of their ability 
to exploit their indigenous knowledge within the world economy.67 This 
led to a worldwide campaign to cancel the patent.68 By allowing for 
patent protection on inventions derived from traditional knowledge, the 
                                                                                                             
60 See 35 U.S.C. § 271(a) (2012) (limiting patent infringement to infringements 
“within the United States” or importation “into the United States.”) 
61 Id. 
62 This use preclusion extends to personal uses only to the extent that patented methods 
are being used inside the United States. The primary impact is with respect to 
commercialization of traditional knowledge because products embodying the patents 
would be shipped to the U.S. 
63 ROBINSON, supra note 35, at 59. 
64 Itsuki Shimbo et al., Patent Protection and Access to Genetic Resources, 26 NATURE 
BIOTECHNOLOGY 645, 645 (2008). 
65 Id. 
66 Shayana Kadidal, Subject-Matter Imperialism? Biodiversity, Foreign Prior Art and 
the Neem Patent Controversy, 37 IDEA 371, 376-77 (1997). But see Emily Marden, The 
Neem Tree Patent: International Conflict Over the Commodification of Life, 22 B.C. 
INT’L & COMP. L. REV. 279, 285 (articulating that effects of the neem patent on Indian 
farmers are unclear and that the patent may help Indian farmers because W.R. Grace 
processes its seeds in India). 
67 Jonathan B. Warner, Using Global Themes to Reframe the Bioprospecting Debate, 
13 IND. J. GLOBAL LEGAL STUD. 645, 651–652 (2006). 
68 Shimbo, supra note 64. 
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use of the traditional knowledge itself amongst indigenous people may 
be eroded.69 
Not only is the patenting of these traditional remedies unfair to the 
indigenous knowledge holders, it is also unfair to the public, who grants 
the “inventors” of these remedies the right to exclude others.70 The grant 
of patent protection to inventors is based on a quid pro quo with society. 
Inventors agree to disclose their discoveries to the public through the 
patent’s specification and, in return, the public grants them an exclusive 
right to exploit those discoveries for a limited time. In this way, both the 
inventor and the public benefit from the protections that patent law 
provides. This paradigm breaks down, however, when the discovery to 
be disclosed is already known to the public. If the invention has been 
used publicly for thousands of years, there is no benefit to the public in 
granting the patentee the exclusive right to exploit it. When well-known 
traditional knowledge is patented, there can be no quid pro quo, and the 
public does not get the benefit of its bargain. 
C. Royalties Paid to Indigenous Knowledge Stakeholders 
In response to the backlash that companies face due to their 
misappropriation of traditional knowledge and pursuant to the Nagoya 
Protocol under the Convention on Biological Diversity (CBD), which 
requires benefit-sharing agreements with indigenous people, companies 
will occasionally pay royalties to indigenous knowledge stakeholders. 
While this scenario is fairer than it would be if no royalties were paid, it 
is accompanied by its own unique set of problems. Conceptions of 
fairness are culturally defined and indigenous peoples are often 
concerned with social, environmental, and spiritual concerns that are not 
accounted for by most profit-sharing agreements.71 Therefore, while the 
payment of royalties may be perceived as “fair” by the pharmaceutical 
companies that are exploiting traditional knowledge, such arrangements 
may not be perceived as fair by the indigenous people themselves.72 
The CBD sought to resolve a fundamental dispute regarding the 
ownership of genetic resources by declaring that states’ sovereign rights 
over natural resources extend to genetic resources.73 This model requires 
a “government-to-government approach,” even though private actors 
                                                                                                             
69 Khor, supra note 59, at 8. 
70 See supra Part I. 
71 Vermeylen, supra note 45, at 425-26. 
72 See id. 
73 Matthias Buck & Claire Hamilton, The Nagoya Protocol on Access to Genetic 
Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization 
to the Convention on Biological Diversity, 20 REV. EUR. COMMUNITY & INT’L L. 47, 47 
(2011). 
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ordinarily conduct transactions in genetic resources and traditional 
knowledge.74 The CBD has raised the level of protection for sovereign 
rights to genetic resources, but has not augmented the level of protection 
for the traditional knowledge holders themselves.75 Moreover, because 
each member government has interpreted the provisions of the CBD 
differently, standards governing the obligations of the parties and the 
fairness of benefit-sharing agreements vary dramatically.76 
A prime example of how these benefit-sharing agreements under the 
CBD fail to compensate most traditional knowledge holders is in the 
treatment of the San people of Southern Africa.77 The San’s traditional 
knowledge relating to consuming Hoodia as an appetite suppressant is 
the subject of a benefit-sharing agreement through South Africa’s 
Council for Scientific and Industrial Research (CSIR).78 Through the 
benefit sharing agreement, the CSIR has permitted companies such as 
Pfizer and Unilever to commercially exploit Hoodia.79 The San never 
granted prior informed consent for the commercialization of their 
traditional knowledge.80 Thus, the San began in a disadvantaged 
bargaining position and did not obtain an equitable benefit-sharing 
agreement. In fact, the vast majority of San people had never even heard 
of the benefit-sharing agreement.81 Under the benefit-sharing agreement, 
the CSIR was to pay the San peoples eight percent of the “milestone 
payments” made by licensees during the drug’s clinical development.82 
After the drug’s development was completed, the San would receive a 
six percent royalty on the marketing of the drug.83 
To make matters worse, the very existence of a benefit-sharing 
agreement disturbed long-standing San values regarding egalitarianism.84 
To facilitate the negotiation of a benefit-sharing agreement, the San were 
pressured to elect leaders, thus changing the nature of group-decision 
making that had previously prevailed in San culture.85 Most of the San 
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people were not consulted regarding the benefit-sharing agreement and 
cared less about monetary compensation than they did about non-
monetary benefits, such as access to education and land.86 They also 
expressed concerns that the money would be wasted and misused by 
public officials.87 These people’s interests were not represented. Not only 
did the majority of the San people not gain any tangible benefit from the 
benefit-sharing agreement, the benefits that were gained came at the 
expense of their traditional mode of decision-making. 
IV. PUSHBACK FROM THE INTERNATIONAL COMMUNITY 
Unsurprisingly, the perceived unfairness of allowing companies to 
expropriate traditional knowledge for their own commercial gain has 
been met with strong international resistance. Countries with vast 
traditional knowledge have sought to protect that knowledge either by 
publishing it in English or by granting property rights in that knowledge 
to the indigenous people. Additionally, international treaties, such as the 
CBD, have sought to address the problem by providing some protections 
for indigenous knowledge stakeholders. This Part explores the two major 
ways that countries rich in traditional knowledge seek to prevent the 
misappropriation of that traditional knowledge, as well as suggestions 
that have been made by the World Intellectual Property Organization 
(WIPO). 
A. Traditional knowledge databases 
The most obvious and effective means of preventing the grant of 
patents based on traditional knowledge is to ensure that the traditional 
knowledge will be considered as prior art. At the most basic level, if 
those opposing the issuance of a patent can demonstrate that the 
“invention” is already known to the public, the invention is ineligible for 
patent protection either because it is not novel or because the invention’s 
improvement over the prior art would have been obvious to person of 
ordinary skill in the art.88 One of the reasons that patents based on 
traditional knowledge have been granted under U.S. law—despite their 
obviousness or lack of novelty—is that foreign “public use” did not 
qualify as prior art.89 Foreign prior art must have been published in 
English to be considered by the USPTO and federal courts.90 In response, 
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various governments and international organizations have created 
traditional knowledge databases that serve as a published written record 
of the traditional knowledge. 
The most inclusive of these databases is WIPO’s “Centralized 
Access to Search and Examination” (CASE) database. While not 
specifically directed at traditional knowledge, CASE facilitates 
communication amongst patent offices worldwide.91 This allows patent 
examiners to view patent applications in other participating jurisdictions 
and share their own examination results.92 For instance, if a patent 
application based on medical uses of indigenous Australian plants is filed 
in the United Kingdom’s Intellectual Property Office, the UK patent 
examiner can access the database to determine whether any similar 
applications had been filed with IP Australia.93 In this way, the scope of 
available prior art and the accessibility of that prior art are both 
improved. 
WIPO’s PATENTSCOPE Search System provides patent attorneys, 
inventors, and researchers a free and accessible way to search patent 
documents from over thirty participating countries and organizations.94 
In addition to WIPO’s databases, China, India, the Republic of Korea, 
Bioversity International, Peru, the Philippines, the Inuit of Nunavik, and 
the Dene in Canada have all established databases directed specifically 
towards traditional knowledge.95 These databases consist of English 
language documents that have recorded traditional knowledge. 
These traditional knowledge databases have had a measurable impact 
on the subject matter of patents that have been granted. For instance, 
following the EPO’s adoption of India’s traditional knowledge database, 
new patents based on herbal formulations were ninety-six percent more 
likely to be a mix of herbal and synthetic formulations.96 This trend is 
likely the result of patent applicants seeking to avoid the prior art. 
Synthetic formulations are more likely to be novel than herbal ones. 
Therefore, if a patent applicant can improve upon traditional herbal 
                                                                                                             
91 WIPO CASE—Centralized Access to Search and Examination, WIPO, http://www.
wipo.int/case/en/ (last visited Mar. 29, 2015). 
92 Id. 
93 IP Australia is Australia’s administrative body that “administers intellectual property 
rights and legislation relating to patents, trademarks, designs and plant breeder’s rights.” 
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95 WIPO, PROGRESS REPORT ON THE STATUS OF TRADITIONAL KNOWLEDGE AS PRIOR 
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remedies by introducing some synthetic component, that applicant is 
more likely to avoid the novelty and non-obviousness issues that are 
associated with deriving an invention from traditional knowledge. By 
forcing patent applicants to consider a broader range of prior art, 
traditional knowledge databases have spurred innovation. Not only do 
databases preclude patents based on existing traditional knowledge, they 
force inventors to improve upon traditional remedies through additional 
innovation. 
B. Sui Generis: Granting property rights in traditional 
knowledge 
While establishing traditional knowledge databases is focused on 
preventing third parties from obtaining intellectual property protection 
for traditional knowledge, some countries have affirmatively provided 
for intellectual property protection to traditional knowledge stakeholders. 
This sort of system, which creates new categories of intellectual property 
rights for traditional knowledge, has been characterized as a sui generis 
regime.97 Thailand, for example, has extended intellectual property 
protection to traditional Thai medicine through the Act on Protection and 
Promotion of Traditional Thai Medicinal Intelligence.98 Under this 
statute, the rights holder has the sole right to produce, distribute, or 
improve upon the medicine.99 Anyone seeking to use Thai traditional 
medicine for commercial benefits is required to apply to “obtain 
benefits” and must pay fees for their use of the traditional medicine.100 
While this law will likely deter or prevent some of the types of 
misappropriation described in this article, it opens the door to domestic 
misappropriation of traditional medicine and alienates the indigenous 
people themselves. Indigenous Thai peoples, such as the Karen, hold 
views regarding traditional medicines, and the herbs that create them, 
that are fundamentally incompatible with intellectual property 
protection.101 The Karen people reject the viewpoint that natural 
                                                                                                             
97 See J. Janewa OseiTutu, A Sui Generis Regime for Traditional Knowledge: The 
Cultural Divide in Intellectual Property Law, 15 MARQ. INTELL. PROP. L. REV. 147, 150–
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resources, such as herbs, should be considered resources at all.102 They 
believe that plants and animals have spirits and should be respected like 
humans are.103 Thus, medicines should not be hoarded and should not be 
traded for a profit.104 If medicinal herbs are abused through commercial 
exploitation, practitioners of traditional Karen medicine would perceive 
this as an abuse of the herbs’ spirit and internalize that harm.105 
Ironically, by refusing to grant patents on such knowledge, the U.S. 
patent system may be more consistent with traditional Karen values than 
the Thai system. The Act on Protection and Promotion of Traditional 
Thai Medicinal Intelligence may enable local practitioners of traditional 
medicine to claim a monopoly on the use of certain remedies. The law’s 
requirement that users of traditional medicine pay royalties is 
inconsistent with the Karen people’s beliefs relating to the use of these 
herbs. From the Karen’s perspective, commercialization and the grant of 
exclusive rights over the medicinal use of certain herbs would be an 
abuse of the herb’s spirit and would cause a spiritual injury to indigenous 
medical practitioners themselves.106 Rather than protecting traditional 
knowledge stakeholders, as they purport to do, these types of laws can be 
adverse to the interests of indigenous peoples if they do not carefully 
consider local religion and customs. By contrast, the AIA would not 
allow a patent on this traditional knowledge and consequently would 
preserve the spiritual integrity of Karen medicine. 
C. WIPO Progress Report on the Status of Traditional 
Knowledge as Prior Art 
Although WIPO has not undertaken to attempt to solve the issue of 
biopiracy, it has made suggestions to member states that seek to resolve 
whether traditional knowledge should qualify as prior art.107 WIPO’s 
Progress Report on the Status of Traditional Knowledge as Prior Art 
identifies two particular problems in establishing traditional knowledge 
as prior art.108 First, the definition of prior art in many jurisdictions 
excludes most traditional knowledge.109 For example, U.S. patent law 
effectively excluded most traditional knowledge as prior art before the 
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enactment of the America Invents Act.110 Second, on a practical level, 
traditional knowledge may be difficult for patent examiners to 
discover.111 Traditional knowledge, even when it is recorded in databases 
or other writings, is often not arranged in an orderly manner.112 It is 
difficult to search, which diminishes its value to patent examiners 
looking for prior art. 
To address these issues, WIPO suggests that IP offices and 
traditional knowledge documentation initiatives “build bridges” to enable 
more effective communication.113 To facilitate this bridge-building, 
WIPO suggests that member nations begin by establishing more efficient 
classification systems.114 While the International Patent Classification 
(IPC) system is extremely effective and is used on ninety-five percent of 
all patent documents, a more detailed system is needed for traditional 
medicine.115 One such example is India’s Traditional Knowledge 
Resource Classification (TKRC) system.116 A more detailed and 
organized system for arranging traditional knowledge would allow 
people to find the relevant prior art that they are looking for. 
V. CHANGES IN THE SCOPE OF “PRIOR ART” 
Some of the most widely debated reforms under the America Invents 
Act are contained in the new Section 102. One of the primary goals of 
the America Invents Act was to bring the U.S. patent system in line with 
the rest of the world.117 Section 102 served as one of the primary vehicles 
for accomplishing that goal, in part, by eliminating geographic 
restrictions on public use, sale, or knowledge as prior art.118 This 
dramatic shift in the scope of prior art to the U.S. patent system is likely 
to have unforeseen consequences in the context of biopiracy and the 
protection of traditional knowledge. Public knowledge, sale, or use of 
traditional knowledge outside the United States may now serve as prior 
                                                                                                             
110 See supra Part II. 
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art to U.S. patents. Thus, applicants seeking U.S. patent protection based 
in part upon traditional knowledge may have more difficulty prosecuting 
and maintaining patents due to the changes to Section 102, which 
effectively renders most traditional knowledge ineligible for patent 
protection in the United States. 
A.  Substantive changes to U.S. patent law under the America 
Invents Act 
Under the 1952 Patent Act, a person could not obtain a patent if “the 
invention was known or used by others in this country, or patented or 
described in a printed publication in this or a foreign country, before the 
invention thereof by the applicant for a patent.”119 By the plain language 
of the statute, the only foreign art that could serve as a bar to a U.S. 
patent were patents and printed publications. U.S. courts applied this 
requirement strictly, rejecting challenges to the novelty or non-
obviousness of U.S. patents based on a foreign public use of the 
invention.120 In the context of biopiracy, this rule presented a significant 
challenge to those attempting to protect the interests of traditional 
knowledge stakeholders. Traditional knowledge is rarely published, so it 
rarely served as prior art to U.S. patents. 
The disputes surrounding the patentability of compounds derived 
from the neem tree embodied this very problem. In the early 1990s, 
American researchers found a way to improve upon a traditional Indian 
pesticide derived from the neem tree by making it suitable for long-term 
storage.121 Although this improvement, arguably, would have been 
obvious to Indian farmers, under Section 102 foreign knowledge could 
only serve as a bar to a U.S. patent if it was published prior to the 
“invention” by the U.S. applicant.122 In 1995, a coalition of 225 groups 
and over 100,000 individual farmers filed a petition with the USPTO 
seeking to invalidate the patent.123 Although a similar patent124 was 
invalidated by the European Patent Office (EPO),125 the U.S. patent 
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remains valid because pre-AIA law continues to apply to patents granted 
before the AIA took effect.126 These differing results are likely explained 
by the difference between the EPO, which is permitted to consider 
foreign knowledge, and the old Section 102, which excluded such 
knowledge if it was not published. 
Since the passage of the America Invents Act, however, the scope of 
prior art under the U.S. patent system has been brought in line with the 
European system. The new Section 102 removed the “in this country” 
limitation that used to apply to the “public use” and “on sale” bars. It 
also added the phrase “available to the public” to “clarify the broad scope 
of relevant prior art.”127 U.S. law no longer requires publication for 
foreign prior art to block a U.S. patent. Prior art for patents issued under 
the American Invents Act “will no longer have any geographic 
limitations.”128 
The changes to Section 102 also included the addition of “or 
otherwise available to the public” as a broad category of prior art. While 
Congress indicated that the purpose of the phrase “available to the 
public” was “to clarify the broad scope of relevant prior art, as well as to 
emphasize the fact that it must be publically available,” there was no 
guidance as to what type of prior art was covered by this phrase and not 
the remainder of Section 102(a)(1).129 One interesting postulation as to 
the different prior art covered by “or otherwise available to the public” is 
that the clause could include orally transmitted information that had yet 
to be physically recorded.130 Though appearing inadvertent, this change 
to Section 102 by the AIA may further assist in the use of traditional 
knowledge as prior art. 
In hypothetically considering the neem-related patents as being 
subject to the post-AIA patent rules, testimony regarding the hundreds of 
years of public use of the neem tree as a pesticide, orally transmitted 
information regarding its effectiveness, and foreign public use of the 
neem tree would all be admissible to show that the American “invention” 
lacks novelty or is obvious.131 
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B. Limitations of the administrative process 
Through the increasingly adversarial model of the USPTO’s 
administrative system, the patent system as a whole has a tendency to 
correct itself. As in the case of the Turmeric Patent, third parties may 
participate in the administrative process and obtain cancellation of 
invalid patents.132 However, geographic limitations on prior art present a 
substantial obstacle to the USPTO’s ability to perform that function. 
Moreover, although the new Section 102 drastically expands the scope of 
available prior art, the practical limitations of the USPTO and the 
restrictions placed on the administrative system limit the impact these 
changes will have on the issuance of new patents. 
Federal regulations place limits on the availability of particular types 
of documentation and when those documents may be presented by third 
parties. Pre-issuance third party submissions are limited to patents, 
published patent applications, or other printed publications.133 Thus, 
before the USPTO has issued a patent, third parties may only submit 
evidence of public use if that use is contained in a printed publication.134 
In a post-grant review,135 third parties may offer evidence of prior public 
use or sale.136 However, a post-grant review may be sought only within 
nine months of the issuance of the patent.137 Following that nine-month 
period, a third party may initiate an inter partes review,138 but only 
patents and printed publications may be considered as prior art.139 This 
leaves a narrow nine-month window after the issuance of the patent in 
which third parties may submit evidence of public use of the invention to 
the USPTO. 
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C. Federal Court Practice 
Due to the short period in which a patent may be challenged at the 
administrative level based on public use or sale, the courts are likely to 
be the forum in which the AIA’s changes to Section 102 will invalidate 
new patents. Courts will consider both oral and documentary evidence in 
determining whether there has been a public use or sale of products 
embodying the patent. For instance, in Trans-World Mfg. Corp v. Al 
Nyman & Sons, Inc., the Federal Circuit upheld the sufficiency of 
evidence supporting a jury verdict of obviousness based on both oral and 
documentary evidence.140 The jury relied both on photographs of the 
prior art and the testimony of one of the inventors himself.141 
While documentary evidence may be difficult to come by in cases 
involving traditional medicine, oral evidence is still available. At trial, 
cross-examination of inventors may reveal the obviousness or lack of 
novelty of the claimed invention, as it did in Trans-World Mfg. Corp. 
Additionally, those with personal knowledge of how the traditional 
medicine was used may testify as to those facts. The fact that this type of 
evidence is available at trial, but is largely unavailable at the 
administrative level, means that the new Section 102 will have a greater 
impact in patent litigation than in the issuance of new patents. 
However, the trend toward accelerated litigation schedules for patent 
cases may make the timely acquisition of such evidence difficult. In one 
of the more aggressive district courts, the Western District of Tennessee, 
invalidity and unenforceability contentions are due within ninety days 
after an answer is filed.142 In the Eastern District of Texas, a popular 
forum for patent disputes, invalidity and unenforceability contentions are 
due within thirty-five days of the initial case management conference.143 
As of the drafting of this article, there has yet to be a patent 
invalidated by prior art that only became applicable by the removal of the 
geographic limitation from Section 102. Because the post-AIA version of 
Section 102 applies to patents issued from applications having, at any 
time, at least one claim with an effective filing date on or after March 16, 
2013, there should soon be an increase in attention to the broader 
availability of prior art. 
Despite the challenges of putting evidence of foreign public use 
before the USPTO and the difficulties faced in litigation, it is axiomatic 
that a patent is essentially useless if it will be invalidated upon litigation. 
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Therefore, pharmaceutical companies seeking patents relating to 
traditional knowledge are likely to consider the scope of foreign public 
knowledge, use, and sale in drafting their patent claims, even if that 
information will never be presented to the USPTO. 
VI. CONCLUSION 
After the passage of the America Invents Act, U.S. patent law 
theoretically should refuse protection to a larger number of “inventions” 
based on traditional knowledge. However, practical considerations 
significantly limit the effect that the AIA will have on the patentability of 
traditional knowledge. The American regulatory system is likely to 
narrow the practical—as opposed to the statutory—scope of prior art. 
Even if oral traditions in South Africa may qualify as prior art under the 
statute, they will not have that effect at the administrative level unless the 
patent examiner knows of those traditions. Additionally, as demonstrated 
by pharmaceutical companies’ responses to traditional knowledge 
databases, these companies are likely to move towards combining 
remedies derived from traditional knowledge with more synthetic 
elements, thus avoiding novelty and non-obviousness issues. 
When the invention is known to the public before the issuance of a 
patent, there is no need to encourage innovation or disclosure, so there is 
no justification for the grant of patent protection. The America Invents 
Act provides the beginnings of a solution both for this foundational 
problem of U.S. patent law and for the injustice that can result from the 
misappropriation of traditional knowledge. It cannot, however, solve this 
problem entirely. 
One solution would be to eliminate some of the evidentiary 
restrictions in administrative procedures, thereby permitting witness 
testimony regarding foreign public uses. That could be accomplished by 
eliminating those restrictions in inter partes review or by extending the 
time period for post-grant review, which contains fewer evidentiary 
restrictions.  However, this change would add to the USPTO’s already 
considerable workload. It would also change the nature of the 
proceedings such that they may become full adversarial trials bearing 
closer resemblance to litigation in the federal courts than administrative 
proceedings. Individual district courts could also decide to amend 
litigation schedules through local patent rules in a way that would 
provide defendants with more time to locate invalidating foreign prior 
art. Both of these potential solutions would prolong an already lengthy 
and expensive patent litigation process, which would not serve the 
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parties, the courts, or the USPTO well. As is often the case, the law 
cannot provide a perfect solution to this problem. 
Due to practical and procedural constraints on the availability of 
foreign prior art, the impact that the America Invents Act’s expansion of 
the scope of prior art will have remains somewhat unclear. What is clear 
is that the statute now permits traditional knowledge stakeholders to 
introduce evidence of foreign public use in their efforts to invalidate 
controversial patents. This possibility alone may be enough to deter 
companies from drafting patent claims that cover traditional knowledge, 
while allowing them to seek protection for their own innovations. 
